Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat

[1]  M. Kassiou,et al.  Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination† †The authors declare no competing interests. , 2016, MedChemComm.

[2]  M. Ro̸rth,et al.  Muscle dysfunction in cancer patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Wendy B DeMartini,et al.  Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age. , 2012, AJR. American journal of roentgenology.

[4]  R. Baumgartner,et al.  Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study , 2012, Journal of Cancer Survivorship.

[5]  A. McTiernan,et al.  Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Rolland,et al.  Cachexia versus sarcopenia , 2011, Current opinion in clinical nutrition and metabolic care.

[7]  C. Dive,et al.  Biological mechanisms linking obesity and cancer risk: new perspectives. , 2010, Annual review of medicine.

[8]  M. Schulze,et al.  A Case-Control Study on Fat-to-Muscle Ratio and Risk of Breast Cancer , 2009, Nutrition and cancer.

[9]  A. Colao,et al.  Body fat in men with prolactinoma , 2008, Journal of endocrinological investigation.

[10]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[11]  G. Fonarow,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reverse Epidemiology beyond Dialysis Patients: Chronic Heart Failure, Geriatrics, Rheumatoid Arthritis, COPD, and AIDS , 2007, Seminars in dialysis.

[12]  A. Wald,et al.  Interventions for the management of weight and body composition changes in women with breast cancer. , 2007, Clinical journal of oncology nursing.

[13]  A. Sahin,et al.  Benign breast diseases: classification, diagnosis, and management. , 2006, The oncologist.

[14]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[15]  F. López‐Soriano,et al.  Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. , 2005, The international journal of biochemistry & cell biology.

[16]  H. Pijl,et al.  Prolactin release is enhanced in proportion to excess visceral fat in obese women. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  N. Boyd,et al.  A Meta-Analysis of Published Literature on Waist-to-Hip Ratio and Risk of Breast Cancer , 2002, Nutrition and cancer.

[18]  Ming-Feng Hou,et al.  Comparison of breast mammography, sonography and physical examination for screening women at high risk of breast cancer in taiwan. , 2002, Ultrasound in medicine & biology.

[19]  M. Shetty,et al.  Sonographic Findings in Focal Fibrocystic Changes of the Breast , 2002, Ultrasound quarterly.

[20]  S. Shousha,et al.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. , 2001, Journal of clinical pathology.

[21]  G. Nagy,et al.  Prolactin: structure, function, and regulation of secretion. , 2000, Physiological reviews.

[22]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[23]  S. Bianchi,et al.  Benign breast disease and breast cancer: A case‐control study in a cohort in italy , 1991, International journal of cancer.

[24]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[25]  S. Norwood,et al.  Fibrocystic breast disease. An update and review. , 1990, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[26]  C. Key,et al.  Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study , 1987, Cancer.

[27]  J. Kelsey,et al.  Estrogen replacement therapy and fibrocystic breast disease. , 1987, American journal of preventive medicine.

[28]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[29]  M. Breckwoldt,et al.  Serum Prolactin Levels in Patients With Fibrocystic Breast Disease , 1984, Obstetrics and gynecology.

[30]  S. Love,et al.  Fibrocystic Disease of the Breast — A Nondisease? , 1982 .

[31]  C. Lindsell,et al.  Randomized controlled trial , 2016 .

[32]  L. Frohman,et al.  Chapter 20 – Growth Hormone: Structure, Function, and Regulation of Secretion , 2016 .

[33]  B. Guy-grand,et al.  [Metabolism of sex hormones and adipose tissue]. , 1986, Journal de gynecologie, obstetrique et biologie de la reproduction.

[34]  H. Vorherr.  Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. , 1986, American journal of obstetrics and gynecology.

[35]  P. Smaglik,et al.  New Perspectives , 2011, Hormone Research in Paediatrics.

[36]  S. Love,et al.  Sounding board. Fibrocystic "disease" of the breast--a nondisease? , 1982, The New England journal of medicine.